<\/p>\n
Ad hoc announcement pursuant to Art. 53 LR <\/p>\n
Dublin, Ireland–(Newsfile Corp. – March 9, 2026) – Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (\u201cCosmo\u201d) today reports its audited financial results for the fiscal year ended December 31, 2025. The Company also publishes its 2025 Annual Report and ESG Report 2025, available on its corporate website under www.cosmohealthconfidence.com\/key-financial-reports<\/a>.<\/p>\n 2025 marked a year of structural strengthening for Cosmo, with a materially higher proportion of recurring revenues, disciplined cost management, and continued platform expansion across MedTech AI and Dermatology. The business model continues to transition toward predictable, scalable recurring revenues and is supported by capital discipline and strategic optionality. <\/p>\n 2025 Financial Highlights<\/strong> <\/p>\n Dividend<\/strong> <\/p>\n The Board of Directors intends to propose a dividend of \u20ac2.10 per share<\/strong> (2024: \u20ac2.05 per share) at the upcoming Annual General Meeting, reflecting the Company\u2019s solid financial position, growing recurring revenue base, and confidence in long-term value creation. <\/p>\n Giovanni Di Napoli, CEO, stated:<\/strong> \u201c2025 was a year of structural progress for Cosmo. We strengthened the quality of our revenue base, with recurring revenues reaching 85% of total revenues, and delivered EBITDA above guidance while reducing operating expenses. GI Genius\u2122 achieved triple digit recurring growth, Winlevi\u00ae continued double digit expansion, and our balance sheet remains debt free with significant capital flexibility.<\/em> In 2026, our priority will be on disciplined execution and scalable growth. We are building a platform company with increasing recurring revenues, expanding operating leverage, and growing strategic optionality. Our capital position allows us to accelerate innovation while maintaining financial discipline.\u201d<\/em> <\/p>\n Svetlana Sigalova, CFO, added:<\/strong> \u201cOur 2025 results reflect rigorous financial discipline and operational focus. EBITDA exceeded the upper end of guidance, supported by recurring revenue growth and a meaningful reduction in operating expenses. We ended the year with \u20ac128.3 million in cash and no financial debt, positioning Cosmo with strong liquidity and strategic flexibility for 2026 and beyond.\u201d<\/em> <\/p>\n 2026 Financial Guidance<\/strong> <\/p>\n For 2026, Cosmo expects continued double-digit growth in recurring revenues and EBITDA, supported by expansion of the GI Genius\u2122 platform, continued global rollout of Winlevi\u00ae, and disciplined cost management. <\/p>\n This 2026 financial framework excludes potential revenues from pipeline or development stage assets. It reflects the continued shift toward a recurring revenue model with expanding operating leverage and sustained capital discipline. <\/p>\n 2026 Value Drivers<\/strong> <\/p>\n Key drivers for 2026 include: <\/p>\n Vision 2030<\/strong> <\/p>\n Cosmo continues to execute on its Vision 2030<\/strong>, a strategy focused on scaling the Company\u2019s recurring revenue base, strengthening profitability and expanding its portfolio of differentiated healthcare technologies. <\/p>\n Based on the continued growth of its existing portfolio, Cosmo confirms its expectation that recurring revenues to reach approximately \u20ac260 million by 2030<\/strong>, representing a compound annual growth rate (CAGR) of approximately 23%<\/strong>, and with the potential contribution from new product launches currently in development, recurring revenues could reach up to \u20ac480 million by 2030<\/strong>, corresponding to a CAGR of approximately 39%<\/strong>. <\/p>\n Cosmo reiterates that this recurring revenue growth is expected to drive operating leverage and expand profitability, targeting EBITDA of approximately \u20ac65 million from the existing portfolio and up to \u20ac195 million including new product launches by 2030. <\/p>\n Business and Pipeline Updates<\/strong> <\/p>\n GI Genius\u2122<\/strong> <\/p>\n In 2025, GI Genius\u2122 continued its expansion as a scalable AI platform in endoscopy, thereby delivering triple-digit recurring revenue growth year-over-year. The platform advanced across hardware, software and regulatory milestones, thereby strengthening its position in AI-assisted gastrointestinal procedures. <\/p>\n The ongoing EU MDR certification progressed, including integration of ColonPRO for real-time detection, sizing and characterization. In parallel, Cosmo successfully completed the first clinical usability study integrating Apple Vision Pro with GI Genius\u2122, treating 16 patients, with a second study planned for the second half of 2026. <\/p>\n The continued evolution of GI Genius\u2122 as an open AI-enabled platform supports further application expansion and integration initiatives in 2026. <\/p>\n Winlevi\u00ae<\/strong> <\/p>\n Winlevi\u00ae maintained strong commercial momentum in 2025 and was delivering sustained double-digit growth year-over-year. The further strengthened its position as a leading branded topical acne treatment in the United States. <\/p>\n In Europe, EMA approval was granted in fall 2025, with first commercial launches expected in the first half of 2026. Additional regulatory approvals were secured in Mexico, Brazil and South Korea, thus further expanding the global footprint of the compound. Winlevi\u00ae is now marketed across the United States, Canada, Australia, the United Kingdom, New Zealand, Singapore, Malaysia and Jordan. <\/p>\n The continued geographic expansion supports a recurring revenue growth and reinforces Winlevi\u00ae as a key pillar of Cosmo\u2019s dermatology franchise. <\/p>\n Clascoterone 5% Topical Solution \u2013 Androgenetic Alopecia<\/strong> <\/p>\n Cosmo\u2019s Clascoterone 5% topical solution represents a first-in-class, non-systemic approach to androgenetic alopecia. It is directly targeting the androgen-driven mechanism underlying the disease. Androgenetic alopecia affects up to 80% of men by age 70 and represents one of the largest and fastest-growing dermatology markets globally. <\/p>\n The program continues to progress as planned, with 12-month safety and tolerability data expected in spring 2026. This readout is anticipated to represent a key strategic inflection point for the asset, as it will support decisions regarding partnering, geographic expansion and potential commercialization pathways. <\/p>\n With its differentiated topical profile and strong scientific rationale, Clascoterone 5% topical solution has the potential to establish a new therapeutic category in hair loss, addressing a significant unmet need while avoiding the limitations of existing systemic therapies. <\/p>\n Additional R&D Programs<\/strong> <\/p>\n Key Figures<\/strong><\/b> <\/p>\n\n
\n
\n
\n